stockportfolio.pro
Quest Diagnostics Incorporated (DGX)
Healthcare · Diagnostics & Research · NYSE
Quest Diagnostics Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.21B | $7.40B | $7.53B | $7.73B | $9.44B | $10.79B | $9.88B | $9.25B | $9.87B | $11.04B |
| Gross profit | $2.90B | $2.68B | $2.60B | $2.69B | $3.63B | $4.21B | $3.43B | $3.05B | $3.24B | $3.67B |
| Net income | $645.00M | $772.00M | $736.00M | $858.00M | $1.43B | $2.00B | $946.00M | $854.00M | $871.00M | $992.00M |
| Net margin | 8.9% | 10.4% | 9.8% | 11.1% | 15.2% | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
Source: Quest Diagnostics Incorporated SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into DGX stock?
At today's market cap of $22.64B, Quest Diagnostics Incorporated is priced for free-cash-flow growth of about 5.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.36B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -3.1%/yr over the last five fiscal years and revenue 3.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Quest Diagnostics Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DGX in your portfolio →
Quest Diagnostics Incorporated financial history by metric
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Quest Diagnostics Incorporated — frequently asked questions
What is Quest Diagnostics Incorporated's revenue?
Quest Diagnostics Incorporated (DGX) reported revenue of $11.04B for fiscal year 2025, up 11.8% from the prior year, according to its SEC filings.
Is Quest Diagnostics Incorporated profitable?
Yes. DGX earned net income of $992.00M in fiscal 2025, a net margin of 9.0%.
What is DGX's P/E ratio?
Quest Diagnostics Incorporated trades at a price-to-earnings ratio of about 22.6 based on the latest data in our nightly-refreshed cache.
How fast is Quest Diagnostics Incorporated growing?
DGX's revenue grew at roughly 3.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Quest Diagnostics Incorporated have?
As of fiscal year 2025, DGX carried roughly $5.67B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Quest Diagnostics Incorporated's gross margin?
DGX's gross margin was 33.2% in fiscal 2025 — gross profit of $3.67B on revenue of $11.04B.
What is Quest Diagnostics Incorporated's market cap?
Quest Diagnostics Incorporated (DGX) has a market capitalization of about $22.64B, based on the latest data in our nightly-refreshed cache.
When does Quest Diagnostics Incorporated's fiscal year end?
DGX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into DGX stock?
At today's market cap of $22.64B, Quest Diagnostics Incorporated is priced for free-cash-flow growth of about 5.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.36B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -3.1%/yr over the last five fiscal years and revenue 3.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Quest Diagnostics Incorporated's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.